Natco Pharma Limited — Investor Meet, 04-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Natco Pharma reported FY26 revenue of 4,375.9 Cr (down YoY) and PAT of 1,418.5 Cr, including a 115 Cr tax benefit. Q4 revenue was 816.9 Cr and profit 269 Cr. Management projects FY27 revenue at 3,400-3,500 Cr and PAT at 700-750 Cr, acknowledging a significant dip. Growth drivers include Semaglutide, Brazil oncology launches, and the South Africa associate. Future growth (15-25% annually from FY28) relies on diversified portfolio and potential acquisitions. With 2,400 Cr net cash, the company targets M&A outside India. Sentiment is cautiously optimistic, focusing on long-term global diversification and pipeline strength.